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Human immunodeficiency virus type-1 (HIV-1) Vpr is a virion-associated protein implicated to have a role in AIDS
pathogenesis. In regard to the amount of Vpr incorporated into virus particles, the published data vary widely. To address this,
we quantitated Vpr in virus particles derived from diverse sources that are used to evaluate the biological effect of Vpr. Virus
particles from infected cells showed only a small amount of Vpr. Interestingly, virus particles from cells cotransfected with
HIV-1 proviral DNA lacking Vpr coding sequences (NLDVpr) and a Vpr expression plasmid showed a drastic increase
(29.4-fold) in the incorporation of Vpr. Furthermore, cotransfection involving NLDVpr and different concentrations of Vpr
expression plasmid resulted in virus particles containing Vpr in proportion to the Vpr expression plasmid used. The
differences in virus particles with respect to Vpr as revealed by these studies should be taken into account in assessing the
effect of Vpr. © 2001 Academic Press
cINTRODUCTION
HIV-1 infection in humans is associated with a loss of
CD41 T cells and other target cells (Azad, 2000; Bukrin-
ky and Adzhubei, 1999; Emerman and Malim, 1998;
evy, 1998). Interestingly, a massive infection of cells in
he lymphoid organs has been noted even when there is
ow viral burden in the peripheral compartments of the
ody, indicating active viral replication. Hence, the pro-
ression of the disease in the context of HIV-1 infection
ay be linked to the cytopathic effects induced by viral
roteins (Azad, 2000; Bukrinsky and Adzhubei, 1999).
ecently, it has been suggested that this may be due to
combination of direct killing of the infected cells by
irus and indirect effects of viral gene products on by-
tander cells (Azad, 2000; Bukrinsky and Adzhubei,
999). The mechanisms that have been proposed in this
egard are apoptosis, perturbation of host cell mem-
ranes, and a loss of cells through the formation of
ultinucleated syncytia (Azad, 2000; Bukrinsky and
dzhubei, 1999; Levy, 1998). These effects have been
inked to HIV-1-encoded gp120, Tat, Nef, and Vpr (Azad,
000; Bukrinsky and Adzhubei, 1999). Specifically, Vpr
as been shown to result in apoptosis following cell
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Microbiology and Immunology, Thomas Jef-
erson University, 1020 Locust Street, JAH Rm. 461, Philadelphia, PA
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78ycle arrest at the G2 stage (Azad, 2000; Emerman and
Malim, 1998). Apoptotic and antiapoptotic effects both
have been noted depending on the activation status of
the cells and also on the concentration of Vpr (Azad,
2000; Bukrinsky and Adzhubei, 1999). Levy et al. (1994
and 1995) reported that Vpr purified from the serum of
HIV-1-infected individuals and recombinant Vpr gener-
ated through a baculovirus expression system showed
an enhancement of HIV-1 production in latently infected
and primary cells exposed to HIV-1.
Analysis of HIV-1 particles revealed the presence of
several nonstructural proteins of viral origin, in addition
to the structural proteins that are responsible for virus
morphogenesis (Emerman and Malim, 1998; Levy, 1998).
These include Vif, Vpr, and Nef, which are shown to be
present in different amounts in the virus particles. It has
also been noted that both Vif and Nef are incorporated
into heterologous retrovirus particles (Azad, 2000; Emer-
man and Malim, 1998; Levy, 1998) as well as into parti-
cles directed by the HIV-1 structural protein Gag. The
incorporation of Vpr, on the other hand, has been shown
to be specific, involving the distinct p6 domain of Gag
(Emerman and Malim, 1998; Levy, 1998). Besides its
essential role in the infection of macrophages by HIV-1,
the characteristic features of Vpr include cell cycle arrest
at the G2 stage, nuclear localization, nuclear import of
the preintegration complex, cation-selective channel ac-
tivity, and interactions with several candidate cellular
proteins (Azad, 2000; Bukrinsky and Adzhubei, 1999;
Emerman and Malim, 1998; Levy, 1998). Work carried out
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79DIFFERENTIAL LEVEL OF Vpr IN VIRIONSby our laboratory and others has shown the importance
of putative helical domains present in Vpr for its incor-
poration into virus particles (Mahalingam et al., 1995,
997; Singh et al., 2000a; Subbramanian et al., 1998; Yao
t al., 1995). Studies by several investigators indicated
hat Vpr is a potent activator of transcription from HIV-1
TR and heterologous promoters including cytokines
Azad, 2000; Bukrinsky and Adzhubei, 1999; Emerman
nd Malim, 1998).
A central question in understanding the role of Vpr for
IDS pathogenesis through virion-associated, cell-asso-
iated, and extracellular Vpr pertains to the amount of
pr present in each of the compartments. While the level
f Vpr expression in virus-infected and HIV-1 proviral
NA transfected cells has not yet been evaluated, there
s information available regarding the extracellular Vpr
serum and cerebrospinal fluid) (Levy et al., 1994, 1995).
ith respect to the amount of Vpr present in the virus
articles, it was reported earlier that the number of Vpr
olecules may be similar to that of Gag (Cohen et al.,
990). On the other hand, Kobinger et al. (1998) reported
hat the number of molecules of Vpr incorporated into the
irus particles is similar in amount to that of reverse
ranscriptase (RT) molecules. This estimation was based
n generating radiolabeled virus particles followed by
mmunoprecipitation using antibodies specific to Vpr and
T. The underlying assumption with these approaches is
hat the affinities of the antibodies used for the analysis
emain the same for both proteins. However, it is likely
hat differences in reactivities of the antibodies may lead
o conclusions that may not be reflective of the amount of
pr protein in virus particles. Furthermore, it was also
eported that Vpr incorporation occurred at essentially
he same level in the virus particles whether Vpr was
xpressed in cis (in context of HIV-1 proviral DNA) or
hrough a heterologous promoter (Hrimech et al., 1999;
oon et al., 1998). Recently, we utilized an epitope tag-
ing approach whereby the flag epitope was added to
oth Gag and Vpr to monitor the stoichiometry of these
roteins in the virus particles. It was determined that the
atio of Gag to Vpr in virus particles, when Vpr-FL is
xpressed in cis (in the context of proviral DNA), is in the
ange of 150–200:1 (14–18 molecules of Vpr per virion).
he expression of Vpr-FL in trans through a heterologous
romoter showed an efficient incorporation with a Gag to
pr ratio of 5–7:1 (392–550 molecules) based on 2750
olecules of Gag present in each virion (Lai et al., 2000;
ingh et al., 2000). As our results were obtained with Vpr
nd Gag containing the flag epitope, there is a possibility
hat the estimated number may be skewed due to the
ddition of an epitope tag. The goal of the studies pre-
ented here was to determine the amount of native Vpr in
he virus particles. The results show that there is a
rastic difference in the amount of Vpr in the virus par-icles generated through virus infection or transfection of
IV-1 proviral DNA.
i
rRESULTS AND DISCUSSION
To quantitate the amount of Vpr in the virus particles,
e considered virus particles from diverse sources that
re routinely used by investigators for functional studies
elated to Vpr. These include virus particles derived from
ells infected with virus, transfected with HIV-1 proviral
NA, or cotransfected with HIV-1 proviral DNA lacking
pr expression (NLDVpr) with a Vpr expression plasmid.
e used polyclonal Vpr antisera raised against a full-
ength synthetic Vpr molecule for these studies (Ma-
alingam et al., 1995). Based on our earlier data (Lai et
l., 2000; Singh et al., 2000), we initially subjected the
irus particles to immunoblot analysis directly from cul-
ure supernatant or purified through a 30% sucrose cush-
on to determine the sensitivity of the assay and the
mount of virus particles to be used. For this purpose,
irus particles were generated by cotransfection of HIV-1
roviral DNA lacking Vpr (NLDVpr) and a Vpr expression
lasmid into 293T cells. The virus particles were quan-
itated by a p24 antigen assay and varying amounts of
irus lysate (2–12 ng) were used for immunoblotting. The
esults shown in Fig. 1A indicate that the intensity of the
pr band is proportional to the virus concentration tested
n the range of 2–12 ng (Fig. 1B). These data support the
act that the assay employed here is sensitive and re-
uires only a minimum amount of virus. We next used 10
g p24 antigen equivalent of virus to analyze virus par-
icles from diverse sources. The results are shown in Fig.
A. The virus particles collected from the culture super-
atant of the cells infected with virus showed a faint
ignal with Vpr antibodies (Fig. 2A, lane3) in comparison
o virus particles derived from cells transfected with
IV-1 proviral DNA (NL4-3) (lane 2) and also from cells
otransfected with HIV-1 proviral DNA lacking the ability
o express Vpr (NLDVpr) with a Vpr expression plasmid
lane 4). Specifically, an intense signal was observed
ith the virus particles derived from cells upon cotrans-
ection. The specificity of incorporation of Vpr was evi-
ent by the lack of a signal with NLDVpr-derived virus
lane 1) and also with virus particles derived from cells
otransfected with NLDVpr and Vpr substitution mutants
pr F34S, Vpr L39G, and Vpr G43P (data not shown).
ensitometry scanning analysis showed that the extent
f incorporation of Vpr into the virus particles from cells
ransfected with proviral DNA was noted to be 2.5 times
hat of Vpr in the virus particles derived from infected
ells (Fig. 2B). Strikingly, a 29.45-fold increase of Vpr
ncorporation was observed in the virus particles derived
rom cotransfected cultures. These data are in agree-
ent with the results obtained with an epitope-tagged
pr and indicate that the extent of incorporation of Vpr
an be influenced by the level of Vpr in cells.
Based on this information, we then considered exper-
ments to address whether the amount of Vpr incorpo-
ated into the virus particles directly correlates with the
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80 SINGH ET AL.concentration of Vpr expression plasmid used for analy-
sis. Cotransfection of HIV-1 proviral DNA (NLDVpr) with
varying concentrations of a Vpr expression plasmid was
carried out in 293T cells. To verify the expression level of
Vpr, cells at 72 h post-transfection were lysed and an
aliquot of the lysate was subjected to immunoblot assay.
Analysis with 50 ug total cellular protein showed a Vpr
band in cells transfected with different amounts of Vpr
expression plasmid in a concentration-dependent man-
ner (Fig. 3A). Immunoblot analysis of virus particles re-
vealed that there is a linear increase in the amount of Vpr
incorporated into the virus particles when cotransfection
with a Vpr expression plasmid was in the range of 1–4
FIG. 1. Immunoblot analysis of virus particles using polyclonal anti-
sera to Vpr. (A) Virus particles, generated by co-transfection of NLDVpr
(5 ug) and Vpr expression plasmid (5 ug) into 293T cells, were col-
lected, centrifuged at 40,000 rpm for 3 h at 4oC through a 30% sucrose
cushion, and lysed in lysis buffer. Varying amounts of virus lysate,
based on p24 antigen values, were immunoprecipitated with polyclonal
antisera to Vpr and immunoreactive proteins were detected using the
ECL Plus western blotting detection system. (B) Quantitation of Vpr
from (A) was performed by densitometry using Personal Densitometer
SI and ImageQuant software. The chemiluminescence intensity of an
individual band was plotted against the amount of virus lysate to
generate a standard curve.mg (Fig. 3B). Transfection of higher concentrations of the
Vpr expression plasmid (6 and 8 mg) showed a reducedlevel of Vpr incorporation in comparison to virus particles
derived from cotransfection involving 4 mg. The densito-
metric analysis of the band corresponding to Vpr showed
a 12-fold increase in Vpr incorporation at 4 mg in com-
parison to 1 mg Vpr expression plasmid used for cotrans-
ection (Fig. 3C).
Based on the data presented, the conclusions are the
ollowing: (i) native Vpr molecules are present in HIV-1
articles in low amounts in relation to the structural
rotein Gag; (ii) virus particles derived from cells infected
ith viral isolates showed less Vpr in comparison to virus
articles generated through transfection of HIV-1 proviral
NA; and (iii) the extent of incorporation of Vpr into the
irus particles, generated through cotransfection of
LDVpr with a Vpr expression plasmid, is high and linear
ith respect to the concentration of the Vpr expression
lasmid used. The literature published thus far state that
IV-1 Vpr is present in amounts similar to that of Gag
rotein in the virus particles as noted for Vpx of HIV-2/SIV
Henderson et al., 1988). Recently, it was reported that
he amount of Vpr in the virus particles is comparable
hether Vpr is expressed in cis (through HIV-1 proviral
NA) or in trans (through a heterologous promoter) and
as the basis to utilize virus particles containing Vpr
FIG. 2. Comparison of Vpr present in the virus particles. (A) Amount
of Vpr in virus particles derived from diverse sources. Transfection of
HIV-1 proviral DNA into 293T cells was carried out by the calcium
phosphate co-precipitation method. CEMX174 cells were used as tar-
get cells for virus infection studies. Virus lysate (10 ng p24 antigen
equivalent) was subjected to immunoblot analysis using polyclonal
antisera to Vpr and the proteins were detected using the ECL Plus
western blotting detection system. (B) Densitometric scanning analysis
of Vpr using Personal Densitometer SI and ImageQuant software.
Lanes 1 and 2, virus particles derived from cells transfected with
NLDVpr and NL4–3, respectively. Lane 3, virus particles derived from
NL4–3 virus infected cells. Lane 4, virus particles from cells cotrans-
fected with NLDVpr and Vpr expression plasmid.
81DIFFERENTIAL LEVEL OF Vpr IN VIRIONS(expressed in trans) for evaluating the functional role of
virion-associated Vpr (Hrimech et al., 1999; Poon et al.,
1998). The basis for the discrepancy between the data
presented versus other studies may be due to the differ-
ences in the techniques used for evaluation, use of
antibodies with differing affinities, and the high amount
of virus particles used in the analysis. The availability of
a large number of HIV-1 proviral DNA molecules in cells
due to the transfection process may result in large
amounts of Vpr expression, in comparison to the level of
Vpr in virally infected cells. This may lead to an increase
in the incorporation of Vpr into the virus particles. A
30-fold increase in the virion incorporation of Vpr in the
FIG. 3. Effect of varying amounts of Vpr expression plasmid on virion
incorporation of Vpr. (A) Expression of Vpr in cells. HIV-1 Vpr was
expressed by cotransfection of NLDVpr (5 ug) with a variable amount of
Vpr expression plasmid into 293T cells. Total cellular protein (50 ug)
was used for immunoblotting to assess the expression of Vpr. (B) Extent
of incorporation of Vpr into the virus particles. Equal amounts of virus
lysate, based on p24 antigen values, were immunoprecipitated with
polyclonal antisera to Vpr, as described in Materials and Methods. (C)
Quantitation of Vpr from (B) using Personal Densitometer SI and Im-
ageQuant software. The fold increase in the incorporation of Vpr was
calculated as 1 using data obtained from cotransfection involving 1 ug
of Vpr expression plasmid.cotransfection setting may be linked to a high level of
expression of Vpr by a heterologous promoter. Vpr isconsidered to be the late gene and its expression is
controlled by the regulatory gene product of HIV-1, Rev.
However, the placement of Vpr under the control of a
heterologous promoter eliminates regulated expression
resulting in high levels of Vpr. Considering the cotrans-
fection method involving HIV-1 proviral DNA lacking the
ability to synthesize Vpr and a Vpr expression plasmid, it
is likely that the resulting virus particles may be a mixture
of particles with Vpr and particles without Vpr. It is inter-
esting to note that an immunoblot analysis using equiv-
alent amounts of virus particles from virally infected cells
and cotransfected cells showed a high amount of Vpr
despite a possible mixture of viruses from cotransfected
cells. This indicates that Vpr expression in trans through
a heterologous promoter leads to an enhanced incorpo-
ration of Vpr into the virus particles. NLVpr proviral DNA
is ;15 Kb in size and the Vpr expression plasmid is only
5.2 Kb. This would translate into three times more mol-
ecules of Vpr expression plasmid as opposed to proviral
DNA plasmid. Given this, it is likely that both plasmids
may be able to enter the target cells because of the
excess of Vpr expression plasmid.
Despite the demonstration that HIV-1 Vpr is a bona
fide virion-associated protein, the underlying mecha-
nism for the incorporation of Vpr into the virus parti-
cles is not clear. Any model regarding this should take
into account the following observations: (a) HIV-1 Gag
is a multimeric protein and is present in the range of
2000–2750 copies per virion (Levy, 1998; Turner and
Summers, 1999); (b) p6 domain of Gag, which lacks a
stable tertiary structure, is essential for virion incor-
poration (Turner and Summers, 1999); (c) earlier stud-
ies indicated that Vpr exhibits oligomerization proper-
ties; and (d) the incorporation of Vpr molecules into the
virus particles is low when Vpr is expressed in the
context of HIV-1 proviral DNA and a high level of
incorporation is noted when Vpr is expressed through
a heterologous promoter. Based on these observa-
tions, it is conceivable that Vpr may interact with
multimeric Gag either as a monomer or as an oligomer
depending on the expression level of Vpr in cells. In
addition, the ability of Vpr to interact with multiple
cellular proteins may restrict the availability of Vpr to
interact with Gag for its incorporation into the virus
particles. The results reported here raise several in-
teresting issues such as (i) how much Vpr is present in
producer cells and in virus particles; (ii) what is the
ratio of Gag to Vpr in producer cells and in virus
particles; and (iii) is there a variation in the amount of
Vpr present in virus particles produced by specific
target cells such as T-cell lines, PBMCs, and macro-
phages? The answers to these questions, in our view,
are critical to understanding the contribution of Vpr
toward AIDS pathogenesis.
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82 SINGH ET AL.MATERIALS AND METHODS
Cell lines
293T, a human transformed primary embryonal kidney
cell line, was maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) and CEMX174 cells were maintained in
RPMI 1640 medium (GIBCO BRL Laboratories, Grand
Island, NY), supplemented with 1% L-glutamine, penicil-
lin–streptomycin, and 10% fetal bovine serum (FBS) at
37°C in 5% CO2.
Transfection and generation of virus particles
HIV-1 proviral DNA (pNL4-3) was modified to disrupt
the expression of Vpr by an insertion (AATT) between
residues 63 and 64 within the Vpr coding region
(NLDVpr). The cloning of wild-type Vpr in pCDNA3 was
carried out with primer pairs HKVpr 59 TCTAGAAGCTT-
GCCGCCACCATGGAACAAGCCCCAGAAGAC 39 (for-
ward) and Vpr-XHO 59 CTAGATGCATGCTCGAGCTAG-
GATCTACTGGCTCCATT 39 (reverse) using PCR method-
ology (Singh et al., 2000). To generate virus particles
containing wild-type Vpr, NLDVpr proviral DNA was co-
transfected with Vpr expression plasmid by the calcium
phosphate coprecipitation method into RD cells (Singh et
al., 2000). Similarly, transfection of NL4-3 containing an
intact open reading frame for Vpr was carried out to
generate virus particles for assessing the amount of Vpr
in transfected cells. The virus particles released into the
culture supernatant were collected 120 h after transfec-
tion. The culture supernatants were pre-cleared for 10
min at 10,000 rpm and subsequently spun at 40,000 rpm
for 3 h using a 30% sucrose cushion. Virus pellets were
lysed in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 0.2% SDS,
1% b-mercaptoethanol, 10% glycerol) and p24 antigen
ssay was used to quantitate the amount of protein
resent in the virus particles.
nfection of CEMX174 cells
Infection of CEMX174 cells was initiated using an in-
culum of 1 ng p24 antigen equivalent of virus generated
rom proviral DNA NL4-3. After 1 h of infection, the cells
ere washed twice with PBS to remove the virus and
esuspended in RPMI medium. Virus replication was
onitored periodically from the medium of the infected
ells by a p24 antigen assay. At the end of 10 days,
ulture supernatant was collected, pre-cleared for 10 min
t 10,000 rpm, and subsequently centrifuged at 40,000
pm for 3 h at 4°C using a 30% sucrose cushion. Virus
ellets were lysed in lysis buffer and quantitated using a
24 antigen assay.
mmunoblot analysis
Virus samples, normalized on the basis of p24 antigen
alues obtained using ELISA (Organon Teknika, Durham,
C), were immunoprecipitated with polyclonal antiserum Lo Vpr and protein A sepharose CL-4B (Amersham Phar-
acia Biotech, Piscataway, NJ) at 4°C overnight. The
epharose beads were then washed and boiled in sam-
le buffer for 5 min and immunoprecipitated proteins
ere separated on NuPAGE 10% Bis-Tris gel (Invitrogen,
arlsbad, CA) followed by transfer onto a nitrocellulose
embrane (Bio-Rad, Hercules, CA). Membranes were
locked with 5% non-fat dry milk and incubated with
abbit polyclonal antiserum to Vpr for 2 h. The mem-
ranes were washed three times for 10 min each with
BST (20 mM Tris [pH 7.5], 500 mM NaCl, 0.05% Tween-
0) and then probed with secondary antibody (Goat anti-
abbit IgG (H1L) HRP conjugate; Promega, Madison,
I), washed again with TBST, and developed with the
CL Plus western blotting detection system (Amersham
harmacia Biotech., Piscataway, NJ).
uantitation of Vpr by densitometry
The intensity of individual bands obtained with immu-
oblot analysis was used for determination of the
mount of Vpr present in the virus particles. Blots were
canned using Personal Densitometer SI and Image-
uant software (Molecular Dynamics, Sunnyvale, CA).
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